Article By:
NASDAQ GlobeNewswire
Wednesday, August 8, 2018 5:22 AM EDT
Progenics Pharmaceuticals, Inc. announced today the pricing of an underwritten public offering of 9,090,909 primary shares of its common stock at a public offering price of $8.25 per share.
In this article: PGNX